预测头颈癌再程放疗后肿瘤复发部位:已发表[18F]-FDG PET影像组学特征的外部回顾性验证
本研究在麻省总医院2012至2022年间66例因复发头颈癌接受再程放疗的患者中,选取31例有再放疗前PET者作为外部验证队列,用已发表的[18F]-FDG PET影像组学特征预测局部区域失败部位。原 cutoff 下识别「野内」复发的平衡准确度为70%、阳性预测值为86%,重新校准 cutoff 后分别为78%和89%,接近原文84.5%的平衡准确度。作者认为该特征可高阳性预测值预测再程放疗后「野内」复发,支持PET影像组学用于识别可能从「野内」剂量提升中获益的患者。
要点
- 原 cutoff 下模型识别「野内」复发的平衡准确度为70%、阳性预测值为86%。
- 重新校准 cutoff 后平衡准确度78%、阳性预测值89%,接近原文84.5%。
- 模型通过 LIFEx 软件免费获取,便于外部使用。
核心结论
- 该研究验证了已建立的PET影像组学特征能以高阳性预测值预测再程放疗后「野内」复发,支持PET影像组学识别可能从再程放疗「野内」剂量提升中获益患者的潜力。
研究设计与样本
- 回顾性外部验证研究,麻省总医院2012至2022年间66例因复发头颈癌接受再程放疗的患者中31例有再放疗前PET,构成外部验证队列,采用与原模型相同的影像组学特征(Intensity_histogram_min、Kurtosis、Correlation、Contrast),以补充个体方式投影到已发表的第一主成分上,并按已发表 cutoff 分为两组。
诊断标准与关键数值
- 31例中22例发生第二次局部区域失败,其中12例为「野内」复发、10例为「野外」复发。
- 使用原 cutoff 时,模型识别「野内」复发的平衡准确度为70%、阳性预测值为86%。
- 重新校准 cutoff 后,模型识别「野内」复发的平衡准确度为78%、阳性预测值为89%,接近原文获得的84.5%平衡准确度。
临床应用与阅片要点
- 作者认为该特征支持PET影像组学识别可能从再程放疗「野内」剂量提升中获益患者的潜力。
- 模型可通过用户友好的 LIFEx 软件免费获取。
局限性
- 外部验证队列仅31例,其中22例发生第二次局部区域失败。
- 研究为回顾性研究,来自单一机构麻省总医院2012至2022年间的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study evaluates the efficacy of a previously published [18F]-FDG PET radiomic signature in predicting locoregional failure locations post-reirradiation in head and neck cancer (HNC) patients, using an independent cohort from a different institution.
MATERIALS AND METHODS: Among the 66 patients reirradiated for recurrent HNC at Massachusetts General Hospital between 2012 and 2022, 31 underwent pre-reirradiation PET, constituting the external cohort for this analysis. These patients were characterized using the same radiomic features as the original model (Intensity_histogram_min, Kurtosis, Correlation, and Contrast), projected as a supplementary individual onto the published first principal component, and assigned to one of two groups using the published cutoff. The cutoff was then optimized for the external cohort to determine the loss of performance due to technical or population shifts.
RESULTS: Among the 31 patients, 22 experienced a second locoregional failure, distributed between 12 "in-field" and 10 "outside" recurrences. With the original cutoff, the model achieved a BA of 70% and a positive predictive value (PPV) of 86% for detecting "in-field" recurrences. After recalibrating the cutoff, the model achieved a BA of 78% and a PPV of 89%, close to the 84.5% BA obtained in the original article.
CONCLUSION: The study validates the ability of the previously established PET radiomic signature to predict "in-field" relapses following reRT with a high PPV. These results support the potential of PET radiomics in identifying patients who may benefit from "in-field" dose escalation in reRT schemes. The model is freely available through the user-friendly LIFEx software.
引用
- Beddok A, Grogg K, Nioche C, et al. Predicting tumor recurrence site after reirradiation in head and neck cancer: a retrospective external validation of a published [18F]-FDG PET radiomic signature. Radiol Med. 2025. PMID: 40833475. doi:10.1007/s11547-025-02072-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。